Cargando…

Correction: The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2019
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6377134/ https://www.ncbi.nlm.nih.gov/pubmed/30768650 http://dx.doi.org/10.1371/journal.pone.0212697

Ejemplares similares

The HER3 pathway as a potential target for inhibition in patients with biliary tract cancers
por: Lamarca, Angela, et al.
Publicado: (2018)

HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?
por: Galdy, Salvatore, et al.
Publicado: (2016)

Correction: Molecular profile of BRCA-mutated biliary tract cancers
Publicado: (2020)

Correction to: Comparison of the effects of adjuvant concurrent chemoradiotherapy and chemotherapy for resected biliary tract cancer
por: Kim, Hyera, et al.
Publicado: (2020)

The Role of HER2 Status in the Biliary Tract Cancers
por: Ayasun, Ruveyda, et al.
Publicado: (2023)

Correction: PP2A inhibition overcomes acquired resistance to HER2 targeted therapy
por: McDermott, Martina S. J., et al.
Publicado: (2023)

HER2/neu-directed therapy for biliary tract cancer
por: Javle, Milind, et al.
Publicado: (2015)

Therapeutic implication of HER2 in advanced biliary tract cancer
por: Nam, Ah-Rong, et al.
Publicado: (2016)

Targeting EGFR/HER2 pathways enhances the antiproliferative effect of gemcitabine in biliary tract and gallbladder carcinomas
por: Pignochino, Ymera, et al.
Publicado: (2010)

Correction: Decoupling of the PI3K Pathway via Mutation Necessitates Combinatorial Treatment in HER2+ Breast Cancer
por: Korkola, James E., et al.
Publicado: (2017)

Correction: CDK4/6 inhibition provides a potent adjunct to Her2-targeted therapies in preclinical breast cancer models
por: Witkiewicz, Agnieszka K., et al.
Publicado: (2021)

Antitumour activity of neratinib in patients with HER2-mutant advanced biliary tract cancers
por: Harding, James J., et al.
Publicado: (2023)

Author Correction: High PD-L1 expression is associated with therapeutic response to pembrolizumab in patients with advanced biliary tract cancer
por: Ahn, Soomin, et al.
Publicado: (2020)

HER2 Aberrations as a Novel Marker in Advanced Biliary Tract Cancer
por: Kim, Hongsik, et al.
Publicado: (2022)

Dual HER2 Blockade: An Emerging Option in Metastatic Biliary Tract Cancer?
por: Ricci, Angela Dalia, et al.
Publicado: (2021)

Targeted Therapy for Biliary Tract Cancer
por: Furuse, Junji, et al.
Publicado: (2011)

Targeted Therapy in Biliary Tract Cancers
por: Merla, Amartej, et al.
Publicado: (2015)

Correction: Targeting the autophagy promoted antitumor effect of T-DM1 on HER2-positive gastric cancer
por: Zhang, Jinghui, et al.
Publicado: (2023)

Correction: Aloe-emodin inhibits HER-2 expression through the downregulation of Y-box binding protein-1 in HER-2-overexpressing human breast cancer cells
por: Ma, Jui-Wen, et al.
Publicado: (2019)

Correction: HER2 as a Promising Target for Cytotoxicity T Cells in Human Melanoma Therapy
por: Ma, Juan, et al.
Publicado: (2013)

Correction: Trastuzumab effects depend on HER2 phosphorylation in HER2-negative breast cancer cell lines
Publicado: (2020)

Correction: Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer
Publicado: (2015)

Correction: Galectin-3 as a Marker and Potential Therapeutic Target in Breast Cancer
por: Zhang, Hao, et al.
Publicado: (2020)

Inhibition of WEE1 Potentiates Sensitivity to PARP Inhibitor in Biliary Tract Cancer
por: Seo, Hye-Rim, et al.
Publicado: (2022)

Precision Oncology Targets in Biliary Tract Cancer
por: Farha, Nicole, et al.
Publicado: (2023)

Correction: Reciprocal Regulation of Annexin A2 and EGFR with Her-2 in Her-2 Negative and Herceptin-Resistant Breast Cancer
por: Shetty, Praveenkumar K., et al.
Publicado: (2012)

Deregulated MicroRNAs in Biliary Tract Cancer: Functional Targets and Potential Biomarkers
por: Mayr, Christian, et al.
Publicado: (2016)

Correction: HER2 Phosphorylation Is Maintained by a PKB Negative Feedback Loop in Response to Anti-HER2 Herceptin in Breast Cancer
por: Gijsen, Merel, et al.
Publicado: (2016)

Correction: Identification of Potential Pathway Mediation Targets in Toll-like Receptor Signaling
por: Li, Fan, et al.
Publicado: (2009)

Correction to: Anti-Warburg effect by targeting HRD1-PFKP pathway may inhibit breast cancer progression
por: Fan, Ya, et al.
Publicado: (2021)

Correction: EGFR, HER-2 and KRAS in Canine Gastric Epithelial Tumors: A Potential Human Model?
Publicado: (2015)

Homologous Recombination Repair in Biliary Tract Cancers: A Prime Target for PARP Inhibition?
por: Yin, Chao, et al.
Publicado: (2022)

Correction: Yanghe Huayan Decoction inhibit the capability of trans-endothelium and angiogenesis of HER2+ breast cancer via pAkt signaling
Publicado: (2023)

Correction to: Amino acid metabolism and signalling pathways: potential targets in the control of infection and immunity
por: Tomé, Daniel
Publicado: (2021)

Correction: Amino acid metabolism and signalling pathways: potential targets in the control of infection and immunity
por: Tomé, Daniel
Publicado: (2021)

Targeting Angiogenesis in Biliary Tract Cancers: An Open Option
por: Simone, Valeria, et al.
Publicado: (2017)

Correction: phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
por: Hamilton, Erika, et al.
Publicado: (2013)

Correction to: Casticin inhibits nasopharyngeal carcinoma growth by targeting phosphoinositide 3-kinase
por: Liu, Jingxian, et al.
Publicado: (2021)

Correction: Shikonin inhibits cancer cell cycling by targeting Cdc25s
por: Zhang, Shoude, et al.
Publicado: (2023)

The potential of patient-derived organoids in precision medicine of biliary tract cancer
por: Yáñez-Bartolomé, Mariana, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_1tm6qlgnltmjj9aue827a4vhha